Oncimmune Holdings PLC on Monday reported a narrowed loss for the first half of the fiscal year, as revenue increased six-fold in the period. The AIM-listed immunodiagnostics developer booked a pretax loss of 2.8 million pounds ($3.9 million) in the six months ended Nov. 30, down from a GBP5.4 million loss for the same period a year earlier.

Source: Wall Street Journal February 15, 2021 08:37 UTC